Applied BioMath, LLC Announces Collaboration With Antengene For Systems Pharmacology Modeling In Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Antengene Corporation for the development of a systems pharmacology modeling in immuno-oncology. Applied BioMath will develop a systems pharmacology model for a PDL1/41BB bispecific antibody, ATG-101, in immuno-oncology indications. The model will be used to predict clinical starting and efficacious doses for first-in-human studies. "Antengene Corporation is dedicated to developing first-in-class and/or best-in-class therapies in oncology," said Dirk Hoenemann, M.D., VP, Head of Medical Affairs for Asia Pacific Region (APAC) and Early Clinical Development. "We decided to collaborate with Applied BioMath in an effort to provide ourselves the highest likelihood possible of predicting accurate starting and efficacious doses which is a critical part of our first-in-human studies." Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. "Predicting starting and efficacious doses for first-in-human studies is non-trivial for complex therapeutics such as Antengene's bispecific therapeutic," said Dr. John Burke, Ph.D., Co-Founder, President, and CEO of Applied BioMath. "We have developed algorithms and tools specifically for this purpose that have a proven track record of predicting such doses. We look forward to collaborating with Antengene to support them in this project."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!